Melatonin için Sleep-Related Cognitive Impairment
C Kanıt Küçük çalışmalardan sınırlı kanıt mevcuttur, ancak bazı olumlu sinyaller bulunmaktadır.Well-established for sleep optimization, melatonin may support cognitive function indirectly by promoting glymphatic clearance of beta-amyloid and other metabolic waste during sleep.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'braincited.com';
const params = 'ingredient\u003Dmelatonin\u0026condition\u003Dsleep\u002Dcognitive';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
Sonuç
Well-established for sleep optimization, melatonin may support cognitive function indirectly by promoting glymphatic clearance of beta-amyloid and other metabolic waste during sleep.
Key Study Findings
review
Pediatric Insomnia.
Dose: Melatonin (various doses), CBT-I (behavioral), pharmacologic options (z-drugs, other)
vs: Placebo
Etki: CBT-I most effective treatment; melatonin beneficial in children with ASD or ADHD; limited evidence
None
Other
Banxia Shumi Decoction Improves Sleep and Neural Function in Insomnia Male Rats via BDNF/TrkB/CREB-Dependent Melatonin …
Dose: None
vs: PCPA-induced insomnia model control
Outcome: Sleep quality and cognitive function in rat model
Etki: None
None
Popülasyon: PCPA-induced insomnia male rats
Randomized Controlled Trial
n=322
5 weeks
Double-blind
Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, …
Dose: 20 mg or 50 mg tasimelteon daily
vs: Placebo
Outcome: Latency to persistent sleep (PSG)
Etki: -44.9 min (20mg) / -46.3 min (50mg) vs -28.2 (placebo)
<0.001
Popülasyon: Patients with primary insomnia (sleep onset difficulty)
Review
Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment.
Dose: None
vs: None
Outcome: ISWRD symptom management
Etki: None
None
Popülasyon: Patients with irregular sleep-wake rhythm disorder
review
Insomnia in older adults: A review of treatment options.
Dose: various
vs: Placebo
Etki: None
None
Review
Commonly encountered symptoms and their management in patients with cirrhosis.
Dose: None
vs: None
Outcome: Pain outcomes
Etki: None
None
Popülasyon: Insomnia patients
Key Statistics
15
Çalışmalar
2000
Katılımcılar
↑
Positive
C
Derece
Referenced Papers
Pediatric Insomnia.
Review
Pediatrics in review
2026
Cleveland Clinic journal …
2025
12 atıf
Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment.
Review
Handbook of clinical …
2025
4 atıf
PloS one
2025
1 atıf
Neurochemical research
2025
Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis.
Meta-Analysis
JNCI cancer spectrum
2024
24 atıf
Journal of neurology
2024
21 atıf
Antioxidants (Basel, Switzerland)
2024
17 atıf
Current opinion in …
2024
12 atıf
Frontiers in medicine
2024
4 atıf
La Revue du …
2024
Complementary and alternative treatments for insomnia disorder: a systematic umbrella review.
Systematic Review
Journal of sleep …
2023
12 atıf
Journal of pineal …
2023
7 atıf
Frontiers in neuroscience
2023
5 atıf
Current drug safety
2023
2 atıf
BMJ open
2022
3 atıf
NPJ Parkinson's disease
2022
Progress in neuro-psychopharmacology …
2021
68 atıf
Frontiers in neurology
2021
16 atıf
A Systematic Review of the Efficacy and Safety of Over-the-Counter Medications Used in Older People for the Treatment of Primary …
Systematic Review
The Senior care …
2021
12 atıf
Neural regeneration research
2021
6 atıf
Climacteric : the …
2020
97 atıf
Neurotherapeutics : the …
2020
80 atıf
Current treatment options …
2020
29 atıf
Human brain mapping
2020
15 atıf
Dermatitis : contact, …
2019
7 atıf
Journal of sleep …
2017
1691 atıf
Neurological research
2017
331 atıf
Nutrients
2017
301 atıf
Current treatment options …
2017
56 atıf
Journal of pineal …
2017
45 atıf
Clinical therapeutics
2016
328 atıf
Pediatric Insomnia.
Review
Chest
2016
109 atıf
European heart journal. …
2016
77 atıf
Diabetes, obesity & …
2015
132 atıf
Alcohol (Fayetteville, N.Y.)
2015
122 atıf
Menopause (New York, …
2015
73 atıf
Chest
2013
53 atıf
PloS one
2012
14 atıf
Pharmacological reports : …
2011
99 atıf
Progress in neuro-psychopharmacology …
2011
71 atıf
Der Nervenarzt
2009
6 atıf
Pharmacotherapy
2007
117 atıf
Tidsskrift for den …
2006
Brain research. Molecular …
2005
160 atıf
Reviews of reproduction
1998
381 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 0.5-5 mg/day
- sleepcognitivesupport:
- 0.5-3 mg 30-60 min before bed
Üst sınır: 10 mg/day (higher doses not more effective)
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| Melatonin (various doses), CBT-I (behavioral), pharmacologic options (z-drugs, other) | -- | Positive | -- |
| None | -- | Positive | -- |
| 20 mg or 50 mg tasimelteon daily | 5 weeks | Positive | 322 |
| None | -- | Mixed | -- |
| various | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Positive | 6528 |
| Z-drugs, melatonin, orexin antagonists | -- | Positive | -- |
En iyi alım zamanı: 30-60 minutes before bedtime
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ Daytime drowsiness
- ⚠ Headache
- ⚠ Dizziness
- ⚠ Nausea
- ⚠ Vivid dreams
Bilinen Etkileşimler
- ● Sedative medications (additive drowsiness)
- ● Blood thinners (may increase bleeding risk)
- ● Diabetes medications (may affect blood sugar)
- ● Immunosuppressants (may stimulate immune function)
- ● Oral contraceptives (may increase melatonin levels)
Tolere edilebilir üst alım: 10 mg/day (higher doses not more effective)
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does Melatonin help with Sleep-Related Cognitive Impairment?
Based on 15 studies with 2,000 participants, there is limited but promising evidence that Melatonin may support Sleep-Related Cognitive Impairment management. Our evidence grade is C (Some Evidence).
How much Melatonin should I take for Sleep-Related Cognitive Impairment?
Studies have used various dosages. A commonly studied range is 0.5-5 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Melatonin?
Reported side effects may include Daytime drowsiness, Headache, Dizziness, Nausea. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Melatonin and Sleep-Related Cognitive Impairment?
We rate the evidence as Grade C (Some Evidence). This rating is based on 15 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Sleep-Related Cognitive Impairment
References
- [1] Rayan Kteish et al.. Pediatr Rev. 2026. Pediatric Insomnia. doi:10.1542/pir.2024-006687 PubMed
- [2] Roberto León-Barriera et al.. Cleve Clin J Med. 2025. Insomnia in older adults: A review of treatment options. doi:10.3949/ccjm.92a.24073 PubMed
- [3] Aleksandar Videnovic et al.. Handb Clin Neurol. 2025. Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment. doi:10.1016/B978-0-323-90918-1.00006-X PubMed
- [4] Naoise C Synnott et al.. PLoS One. 2025. Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial. doi:10.1371/journal.pone.0332366 PubMed
- [5] Baojun Guo et al.. Neurochem Res. 2025. Banxia Shumi Decoction Improves Sleep and Neural Function in Insomnia Male Rats via BDNF/TrkB/CREB-Dependent Melatonin Signaling Activation. doi:10.1007/s11064-025-04556-y PubMed
- [6] Eva Rames Nissen et al.. JNCI Cancer Spectr. 2024. Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis. doi:10.1093/jncics/pkae041 PubMed
- [7] Laura Palagini et al.. J Neurol. 2024. Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group. doi:10.1007/s00415-023-12112-3 PubMed
- [8] Kazim Sahin et al.. Antioxidants (Basel). 2024. Impact of a Novel Valerian Extract on Sleep Quality, Relaxation, and GABA/Serotonin Receptor Activity in a Murine Model. doi:10.3390/antiox13060657 PubMed
- [9] Bhavya Narala et al.. Curr Opin Pediatr. 2024. Delayed sleep wake phase disorder in adolescents: an updated review. doi:10.1097/MOP.0000000000001322 PubMed
- [10] Cyriac Abby Philips. Front Med (Lausanne). 2024. Commonly encountered symptoms and their management in patients with cirrhosis. doi:10.3389/fmed.2024.1442525 PubMed
- [11] Marie-Françoise Vecchierini et al.. Rev Prat. 2024. [Pharmacotherapies for insomnia]. PubMed
- [12] Johanna Ell et al.. J Sleep Res. 2023. Complementary and alternative treatments for insomnia disorder: a systematic umbrella review. doi:10.1111/jsr.13979 PubMed
- [13] Hui Yang et al.. J Pineal Res. 2023. RP58 knockdown contributes to hypoxia-ischemia-induced pineal dysfunction and circadian rhythm disruption in neonatal rats. doi:10.1111/jpi.12885 PubMed
- [14] Nijee S Luthra et al.. Front Neurosci. 2023. Targeting neuroendocrine abnormalities in Parkinson's disease with exercise. doi:10.3389/fnins.2023.1228444 PubMed
- [15] Mrinalini Ravikumar et al.. Curr Drug Saf. 2023. The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease. doi:10.2174/1574886317666220517125644 PubMed
- [16] Yulin Sun et al.. BMJ Open. 2022. Melatonin supplementation for the treatment of infantile spasms: protocol for a randomised placebo-controlled triple-blind trial. doi:10.1136/bmjopen-2021-057970 PubMed
- [17] Jingwen Li et al.. NPJ Parkinsons Dis. 2022. Melatonin ameliorates Parkinson's disease via regulating microglia polarization in a RORα-dependent pathway. doi:10.1038/s41531-022-00352-5 PubMed
- [18] Pierre A Geoffroy et al.. Prog Neuropsychopharmacol Biol Psychiatry. 2021. Biological rhythms and chronotherapeutics in depression. doi:10.1016/j.pnpbp.2020.110158 PubMed
- [19] Xiaoli Wu et al.. Front Neurol. 2021. Circadian Rhythm Disorders and Corresponding Functional Brain Abnormalities in Young Female Nurses: A Preliminary Study. doi:10.3389/fneur.2021.664610 PubMed
- [20] Sandrah-Ann M Almond et al.. Sr Care Pharm. 2021. A Systematic Review of the Efficacy and Safety of Over-the-Counter Medications Used in Older People for the Treatment of Primary … doi:10.4140/TCP.n.2021.83 PubMed
- [21] Ning Sha et al.. Neural Regen Res. 2021. The role of pineal microRNA-325 in regulating circadian rhythms after neonatal hypoxic-ischemic brain damage. doi:10.4103/1673-5374.308101 PubMed
- [22] P Proserpio et al.. Climacteric. 2020. Insomnia and menopause: a narrative review on mechanisms and treatments. doi:10.1080/13697137.2020.1799973 PubMed
- [23] José Rafael P Zuzuárregui et al.. Neurotherapeutics. 2020. Sleep Issues in Parkinson's Disease and Their Management. doi:10.1007/s13311-020-00938-y PubMed
- [24] Luigi Ferini-Strambi et al.. Curr Treat Options Neurol. 2020. Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease. doi:10.1007/s11940-020-0612-z PubMed
- [25] Feifei Zhang et al.. Hum Brain Mapp. 2020. The effect of jet lag on the human brain: A neuroimaging study. doi:10.1002/hbm.24945 PubMed
- [26] Aleksi J Hendricks et al.. Dermatitis. 2019. Clinical Pearls on Sleep Management in Atopic Dermatitis. doi:10.1097/DER.0000000000000523 PubMed
- [27] Dieter Riemann et al.. J Sleep Res. 2017. European guideline for the diagnosis and treatment of insomnia. doi:10.1111/jsr.12594 PubMed
- [28] Zizhen Xie et al.. Neurol Res. 2017. A review of sleep disorders and melatonin. doi:10.1080/01616412.2017.1315864 PubMed
- [29] Xiao Meng et al.. Nutrients. 2017. Dietary Sources and Bioactivities of Melatonin. doi:10.3390/nu9040367 PubMed
- [30] Amy W Amara et al.. Curr Treat Options Neurol. 2017. Treatment of Sleep Dysfunction in Parkinson's Disease. doi:10.1007/s11940-017-0461-6 PubMed
- [31] Deetje Iggena et al.. J Pineal Res. 2017. Melatonin restores hippocampal neural precursor cell proliferation and prevents cognitive deficits induced by jet lag simulation in adult mice. doi:10.1111/jpi.12397 PubMed
- [32] Jennifer L Schroeck et al.. Clin Ther. 2016. Review of Safety and Efficacy of Sleep Medicines in Older Adults. doi:10.1016/j.clinthera.2016.09.010 PubMed
- [33] Kelly M Brown et al.. Chest. 2016. Pediatric Insomnia. doi:10.1378/chest.15-0605 PubMed
- [34] Lionel H Opie et al.. Eur Heart J Cardiovasc Pharmacother. 2016. Melatonin has multiorgan effects. doi:10.1093/ehjcvp/pvv037 PubMed
- [35] E Challet. Diabetes Obes Metab. 2015. Keeping circadian time with hormones. doi:10.1111/dom.12516 PubMed
- [36] Kirk J Brower. Alcohol. 2015. Assessment and treatment of insomnia in adult patients with alcohol use disorders. doi:10.1016/j.alcohol.2014.12.003 PubMed
- [37] Hrayr Attarian et al.. Menopause. 2015. Treatment of chronic insomnia disorder in menopause: evaluation of literature. doi:10.1097/GME.0000000000000348 PubMed
- [38] Jeremy A Weingarten et al.. Chest. 2013. Air travel: effects of sleep deprivation and jet lag. doi:10.1378/chest.12-2963 PubMed
- [39] Irina V Zhdanova et al.. PLoS One. 2012. Familial circadian rhythm disorder in the diurnal primate, Macaca mulatta. doi:10.1371/journal.pone.0033327 PubMed
- [40] Monika Banach et al.. Pharmacol Rep. 2011. Melatonin in experimental seizures and epilepsy. doi:10.1016/s1734-1140(11)70393-0 PubMed
- [41] Venkatramanujan Srinivasan et al.. Prog Neuropsychopharmacol Biol Psychiatry. 2011. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? doi:10.1016/j.pnpbp.2011.03.013 PubMed
- [42] Dieter Riemann et al.. Nervenarzt. 2009. [Insomnias. II. Pharmacological and psychotherapeutic treatment options]. doi:10.1007/s00115-009-2746-9 PubMed
- [43] Anna K Morin et al.. Pharmacotherapy. 2007. Therapeutic options for sleep-maintenance and sleep-onset insomnia. doi:10.1592/phco.27.1.89 PubMed
- [44] Anders Johnsson et al.. Tidsskr Nor Laegeforen. 2006. [Rhythms, depressions and light]. PubMed
- [45] Birgit M Dietz et al.. Brain Res Mol Brain Res. 2005. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. doi:10.1016/j.molbrainres.2005.04.009 PubMed
- [46] J Arendt. Rev Reprod. 1998. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. doi:10.1530/ror.0.0030013 PubMed
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.